N,N-二甲基-5,6,7,8-四氢苯并[4,5]噻吩并[2,3-D]嘧啶-4-胺 | 871807-58-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 中文名称: N,N-二甲基-5,6,7,8-四氢苯并[4,5]噻吩并[2,3-D]嘧啶-4-胺
• 英文名称: 4-dimethylamino-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidine
• 英文别名: N,N-dimethyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine；N,N-dimethyl-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-amine
• CAS: 871807-58-8
• 化学式: C₁₂H₁₅N₃S
• mdl: MFCD01192168
• 分子量: 233.337
• InChiKey: QMTYZDOKFYNPJL-UHFFFAOYSA-N

物化性质

• 熔点：
  63 °C
• 沸点：
  396.0±37.0 °C(Predicted)
• 密度：
  1.266±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  57.3
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302,H312,H315,H319
• 储存条件：
  密封于干燥常温环境

反应信息

• 作为产物：
  描述：

  2-氨基-4,5,6,7-四氢苯并噻酚-3-羧酸乙酯 在 三乙胺 、 三氯氧磷 作用下， 以 甲醇 为溶剂， 反应 3.0h， 生成 N,N-二甲基-5,6,7,8-四氢苯并[4,5]噻吩并[2,3-D]嘧啶-4-胺
  参考文献：
  名称：

  [EN] TRICYCLIC PROTEASOME ACTIVITY ENHANCING COMPOUNDS
  [FR] COMPOSÉS RENFORÇANT L'ACTIVITÉ PROTÉASOME TRICYCLIQUE

  摘要：

  公开号：

  WO2012012712A3

文献信息

• Identification of 5,6-substituted 4-aminothieno[2,3-d]pyrimidines as LIMK1 inhibitors
  作者：Brad E. Sleebs、George Nikolakopoulos、Ian P. Street、Hendrik Falk、Jonathan B. Baell

  DOI：10.1016/j.bmcl.2011.07.050

  日期：2011.10

  4-Aminobenzothieno[3,2-d]pyrimidines were previously identified in a high throughput screening campaign as LIMK1 inhibitors. Scaffold reversal led to the identification of a series of simple 5,6-substituted 4-aminothieno[2,3-d]pyrimidines with low micromolar inhibition of LIMK1.

  4-氨基苯并噻吩并[3,2- d ]嘧啶先前在高通量筛选活动中被鉴定为LIMK1抑制剂。支架逆转导致鉴定了一系列简单的5,6-取代的4-氨基噻吩并[2,3- d ]嘧啶，对LIMK1的抑制作用很小。
• Synthesis and study of antiproliferative activity of novel thienopyrimidines on glioblastoma cells
  作者：Stéphane Pédeboscq、Denis Gravier、Françoise Casadebaig、Geneviève Hou、Arnaud Gissot、Francesca De Giorgi、François Ichas、Jean Cambar、Jean-Paul Pometan

  DOI：10.1016/j.ejmech.2010.02.032

  日期：2010.6

  The receptor tyrosine kinases (for example EGFR, PDGFR, VEGFR) are a transmembrane protein family which plays a crucial role in tumor growth, survival, metastasis dissemination and angiogenesis. During the past 10 years, many tyrosine kinase inhibitors (TKIs) have been approved for cancer treatment (imatinib, gefitinib, erlotinib, sunitinib, sorafenib). These compounds generally possess a pyrrolo- or pyrimido- pyrimidine scaffold or approaching molecular structure. We synthesized 10 thienopyrimidine compounds (including 5 newly synthesized) whose scaffold is very similar to the agents cited above. The cytotoxicity of these agents was evaluated using a MTT assay and a flow cytometry technique on glioblastoma cell lines. Two compounds showed a similar cytotoxicity to the standard anti-EGFR gefitinib (IC50: gefitinib = 51.9 mu M, 6b = 61.8 mu M, 6c = 41.2 mu M), suggesting a blockade of the EGFR pathway by binding to the TK receptor.
• EP2595993B1
  申请人：——

  公开号：EP2595993B1

  公开（公告）日：2018-04-18
• Tricyclic Proteasome Activity Enhancing Compounds
  申请人：Finley Daniel J.

  公开号：US20130210845A1

  公开（公告）日：2013-08-15

  Proteinopathies result from the proteasome not acting efficiently enough to eliminate harmful proteins and prevent the formation of the pathogenic aggregates. As described herein, inhibition of proteasome-associated deubiquitinase Usp14 results in increased proteasome efficiency. The present invention therefore provides novel compositions and methods for inhibition of Usp14, enhancement of proteasome activity and treatment of proteinopathies.
• US8933087B2
  申请人：——

  公开号：US8933087B2

  公开（公告）日：2015-01-13